IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroend

Go back to IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroend
(NASDAQ: IDYA) Delayed: 34.71 -1.41 (3.9%)
Previous Close $36.12    52 Week High $ 
Open $36.35    52 Week Low $ 
Day High $36.35    P/E N/A 
Day Low $34.54    EPS $ 
Volume 1,128,966